<DOC>
	<DOCNO>NCT01468272</DOCNO>
	<brief_summary>This pharmacokinetic comparison CHF 1535 50/6 NEXT DPI versus free combination Beclomethasone DPI Formoterol DPI child ( 5 11 year old ) formulation already approve adult .</brief_summary>
	<brief_title>Clinical Pharmacology CHF 1535 50/6 ug Next DPI Children 5-11 Years Old</brief_title>
	<detailed_description>Pharmacokinetic study asthmatic child 5 11 year old treat either fixed combination beclomethasone 50 ug/unit dose plus formoterol fumarate 6 ug/unit dose via NEXT DPI dry powder inhaler free combination Beclomethasone 100 ug DPI Formoterol 6 ug DPI accord cross-over design .</detailed_description>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>1 . Male/Female child age 5 11y 2 . Written inform consent obtain parents/legal representative ( accord local regulation ) minor ( age local regulation permit ) . 3 . Children stable asthma 4 . Children asthma regular treatment ICS use shortacting inhaled beta2agonists reliever control asthma symptom 5 . Forced expiratory volume one second ( FEV1 ) &gt; 70 % predict value ( % pred ) withhold beta2agonists treatment minimum 4 h prior study treatment . 6 . A cooperative attitude ability train proper use DPI compliant study procedure . 1 . Past present diagnosis cardiovascular , renal liver disease 2 . Known hypersensitivity active treatment 3 . Exacerbation asthma symptom within previous 4 week 4 . Inability perform require breathing technique blood sample 5 . Hospitalization due exacerbation asthma within 1 month prior screen ( visit 1 ) 6 . Lower respiratory tract infection within 1 month prior screen ( visit 1 ) 7 . Disease ( asthma ) might influence outcome study 8 . Obesity , i.e . &gt; 97 % weight percentile local standard</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>asthma child NEXT DPI LABA ICS inhalation</keyword>
</DOC>